Trial Profile

A phase III, multicenter, randomized, controlled study of neoadjuvant LHRH [luteinising hormone-releasing hormone]-agonist [gonadotropin releasing hormone agonists] therapy and permanent I-125 [iodine 125] implantation with vs. without adjuvant LHRH-agonist therapy in patients with untreated intermediate-risk prostate cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2020 Biomarkers information updated
26 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
25 May 2011 Planned end date changed from 1 Mar 2010 to 1 Mar 2021 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com